You are hereMay 9, 2019
What´s the Stem Cells Buzz this Week? - Cardiac Differentiation Review, Comparing Hepatic Stellate Cells, ASC Trial for Pneumosepsis, and Advancing Cardiac Cell Therapy!
The Stem Cells Portal brings you a roundup of some of the new and exciting stories in the ever-changing world of stem cells, regenerative medicine, and beyond!
Molecular Mechanisms of Cardiac Differentiation
Human pluripotent stem cell (hPSCs)‐derived cardiomyocytes may be employed for the treatment of severe heart failure, although current protocols generate low yields of immature cells. To help the field advance, researchers from the laboratory of Jun Fujita (Keio University School of Medicine, Tokyo, Japan) have reviewed the literature and now summarize currently employed protocols in the hope of creating a knowledge base for the further development of effective therapies. Furthermore, the team also discuss the future challenges we may face in this field; for this, and more, see STEM CELLS now!
Mesenchymal Stem Cells are Functionally Distinct from Hepatic Stellate Cells
Researchers from the labs of Raghavan Chinnadurai and Jacques Galipeau (University of Wisconsin – Madison, USA) recently compared the immune plasticity of two mesenchymal cell types in the hope of generating insight into their potential utility as pharmaceuticals. In their STEM CELLS study, the authors demonstrate how bone marrow-derived mesenchymal stem cells and hepatic stellate cells display differing secretome profiles and immune functional responses, likely due to their distinct tissular origins. Can we match distinct diseases and disorders with an optimal stem cell type according to their secretome?
Adipose Mesenchymal Stem Cells in Pneumosepsis
Mesenchymal stem cells (MSCs) possess potent immunomodulatory capabilities, and for this reason, researchers from the laboratory of Desirée Perlee (University of Amsterdam, Amsterdam, The Netherlands) recently sought to assess the effect of adipose‐derived MSC therapy on pneumosepsis in mice. In their recent STEM CELLS Translational Medicine article, the authors established that human adipose-derived MSCs induced profound immune modulatory effects in the lungs, resulting in reduced bacterial burdens and lung inflammation, suggesting that MSCs may represent an adjunctive therapy in sepsis.
Expanded CD34+ Cells for Cardiac Cell Therapy
Treatment with autologous peripheral blood‐derived CD34-positive stem cells can prompt repair of the damaged myocardial area following infarction. To advance this approach closer to the clinic, researchers led by Claire Saucourt (CellProthera, Mulhouse, France) recently developed an automated device for ex vivo CD34-positive stem cell expansion beginning with whole blood samples. This new system represents a simplified and standardized means to generate high amounts of CD34-positive cells and has opened the way for a clinical phase I/IIb trial, which is currently recruiting patients with severe acute myocardial infarction. For all the details, see STEM CELLS Translational Medicine!
That’s a wrap for now! Please feel free to leave a comment and discuss the papers covered here on the Stem Cells Buzz. Happy reading!